title: Maternal use of selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn.
abstract: Use of selective serotonin reuptake inhibitors (SSRIs) in late pregnancy has been associated with persistent pulmonary hypertension of the newborn (PPHN), a rare condition with substantial infant mortality and morbidity. Although the increase in absolute risk is small on a population level, it may be of concern to many patients. It remains unclear the extent to which the increased risks reported for PPHN are explained by the underlying maternal illness rather than the use of SSRIs.
authors.affiliation: Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Alwan
authors.affiliation: Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California, USA.
authors.forename: G
authors.initials: G
authors.lastname: Bandoli
authors.affiliation: Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California, USA.
authors.forename: C D
authors.initials: CD
authors.lastname: Chambers
mesh_terms: D003863:Depression / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D010547:Persistent Fetal Circulation Syndrome / Q000209:etiology* / Q000503:physiopathology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011297:Prenatal Exposure Delayed Effects / Q000503:physiopathology; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors